Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed.
Citations
Citations to this article as recorded by
Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy Hun Kim, Tae Hoon Roh, Jun Seop Lee, Min Seong Kim, Beom Kyung Kim Journal of Liver Cancer.2024; 24(1): 113. CrossRef
Refining MRI-based criteria for portal vein invasion in hepatocellular carcinoma: improving sensitivity beyond portal vein tumor thrombosis Jeongju Kim, Woo Kyoung Jeong, Jong Man Kim, Sang Yun Ha, Kyunga Kim Abdominal Radiology.2023; 49(2): 437. CrossRef
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review Sang Jin Kim, Jong Man Kim Clinical and Molecular Hepatology.2022; 28(4): 739. CrossRef
Hepatocellular adenoma is a benign tumor of the liver occurring predominantly in young women taking oral contraceptives. The malignant transformation of hepatocellular adenoma into hepatocellular carcinoma has rarely been reported. Herein, we report the case of an elderly male patient with hepatocellular carcinoma that developed from hepatocellular adenoma. The patient’s high risk for surgery and conflicting biopsy and imaging results made it difficult to determine the treatment direction. Eventually, the mass was completely removed by laparoscopic left hemi-hepatectomy without complications.
Citations
Citations to this article as recorded by
A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathological and Imaging Features With an Emphasis on β‐Catenin Mutated Subtype Subin Heo, Bohyun Kim, So Yeon Kim, Hyo Jeong Kang, In Hye Song, Sung Hak Lee, Jimi Huh, Seokhwi Kim, Seunghee Baek, Seung Soo Lee, Sang Hyun Choi, Jong Keon Jang, Seong Ho Park Liver International.2025;[Epub] CrossRef
Radiofrequency Ablation versus Surgical Resection in Elderly Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Jeong-Ju Yoo, Sujin Koo, Gi Hong Choi, Min Woo Lee, Seungeun Ryoo, Jungeun Park, Dong Ah Park Current Oncology.2024; 31(1): 324. CrossRef
External beam radiotherapy, transarterial chemoembolization and sorafenib are currently
standard treatments for advanced hepatocellular carcinoma (HCC) with portal vein
thrombosis. However, hepatic arterial infusion chemotherapy has been applied to advanced
stage HCC with a view to improving the therapeutic effect. We experienced a case of
advanced HCC with clinical complete response after hepatic artery infusion chemotherapy
and radiation therapy and report that.
Citations
Citations to this article as recorded by
A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy Jin Yong Lee, Jeong-Ju Yoo, Seong Joon Chun, Sun Hyun Bae, Jae Myeong Lee, Sang Gyune Kim, Young Seok Kim Journal of Liver Cancer.2020; 20(1): 78. CrossRef